Pharmacokinetic Analysis Sample Clauses

Pharmacokinetic Analysis. ‌ Pharmacokinetic analysis will be done using a validated computer program. The PK characteristics of ALXN2050 from patients, including, but not limited to, the standard PK parameters outlined in the table below, will be derived from the individual plasma concentration time data on study day(s) with intensive PK sampling. Descriptive statistics (number of patients, mean/geometric mean, SD, median, minimum, and maximum) will be used to summarize the calculated PK parameters. AUC0-12 Area under the curve Cmax Maximum plasma concentration tmax Time after administration of a drug when the maximum plasma concentration is reached C(0) Trough concentration at start of steady-state dose interval C(12) Trough concentration at end of steady-state dose interval
Sample 1
AutoNDA by SimpleDocs
Pharmacokinetic Analysis. (a) The Parties hereby agree that Novartis shall, at no cost to QED, conduct certain pharmacokinetic analyses and related activities for the clinical study entitled: [***] pursuant to the Statement of Work attached hereto as Schedule 1. The Parties hereby agree that all results of all such activities performed by Novartis pursuant to this Statement of Work, including all reports, records, results, data and other information generated in the conduct of such activities, shall be considered “Novartis Know-How,” notwithstanding anything to the contrary in the definition of “Novartis Know-How” and licensed to QED pursuant to Section 2.1 of the License Agreement. Novartis will conduct such activities in accordance with all Applicable Laws and all applicable industry standards and practices. QED acknowledges that reports, records, results, data and other information generated in the conduct of such activities shall be provided “as is” and without implied warranties of merchantability or fitness for a particular purpose, and any use made by QED of such reports, records, results, data and other information is at its own risk.
Sample 1

Related to Pharmacokinetic Analysis

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Study Population Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: minimum 21 days/3 weeksuntil patient’s weight >2000g, averaged 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months following enterostomy closure (12- month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 months of overall study duration).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!